To investigate whether treatment with AR targeting agents affected the association of PC1 with tumor fraction, we used PCA eigenvectors to project the progression samples, healthy volunteer controls (0 tumor fraction), and the LNCaP prostate cancer cell line (100% tumor, 3 replicates; Figure 2C). The gene discussed is AR; the disease is prostate carcinoma.